97 related articles for article (PubMed ID: 33390333)
1. Upfront surgery or definitive radiotherapy for p16+ oropharyngeal cancer. A GETTEC multicentric study.
Culié D; Schiappa R; Modesto A; Viotti J; Chamorey E; Dassonville O; Poissonnet G; Bizeau A; Vergez S; Dupret-Bories A; Fakhry N; Santini L; Lallemant B; Chambon G; Sudaka A; Peyrade F; Saada-Bouzid E; Benezery K; Jourdan-Soulier F; Chapel F; Ramay AS; Roger P; Galissier T; Coste V; Ben Lakdar A; Guerlain J; Mirghani H; Gorphe P; Guelfucci B; Garrel R; Temam S; Bozec A
Eur J Surg Oncol; 2021 Jun; 47(6):1389-1397. PubMed ID: 33390333
[TBL] [Abstract][Full Text] [Related]
2. Upfront surgery or definitive radiotherapy for patients with p16-negative oropharyngeal squamous cell carcinoma. A GETTEC multicentric study.
Culié D; Viotti J; Modesto A; Schiappa R; Chamorey E; Dassonville O; Poissonnet G; Guelfucci B; Bizeau A; Vergez S; Dupret-Bories A; Garrel R; Fakhry N; Santini L; Lallemant B; Chambon G; Sudaka A; Peyrade F; Saada-Bouzid E; Benezery K; Jourdan-Soulier F; Chapel F; Ramay AS; Roger P; Galissier T; Coste V; Ben Lakdar A; Guerlain J; Temam S; Mirghani H; Gorphe P; Bozec A
Eur J Surg Oncol; 2021 Feb; 47(2):367-374. PubMed ID: 33004271
[TBL] [Abstract][Full Text] [Related]
3. Extracapsular extension of neck nodes and absence of human papillomavirus 16-DNA are predictors of impaired survival in p16-positive oropharyngeal squamous cell carcinoma.
Freitag J; Wald T; Kuhnt T; Gradistanac T; Kolb M; Dietz A; Wiegand S; Wichmann G
Cancer; 2020 Jan; 126(9):1856-1872. PubMed ID: 32032442
[TBL] [Abstract][Full Text] [Related]
4. The Role of Adjuvant Chemotherapy in Surgically Managed, p16-Positive Oropharyngeal Squamous Cell Carcinoma.
Skillington SA; Kallogjeri D; Lewis JS; Piccirillo JF
JAMA Otolaryngol Head Neck Surg; 2017 Mar; 143(3):253-259. PubMed ID: 27918781
[TBL] [Abstract][Full Text] [Related]
5. Outcomes after primary intensity-modulated radiation therapy for oropharyngeal squamous cell carcinoma at a New Zealand regional cancer centre: Impact of p16 status.
Maqsood S; Jameson MB; De Groot C; Hartopeanu C; Yasin NABHM; Thotathil Z
Cancer Rep (Hoboken); 2018 Jun; 1(1):e1001. PubMed ID: 32729235
[TBL] [Abstract][Full Text] [Related]
6. Synchronous primary neoplasia in patients with oropharyngeal cancer: Impact of tumor HPV status. A GETTEC multicentric study.
Milliet F; Bozec A; Schiappa R; Viotti J; Modesto A; Dassonville O; Poissonnet G; Guelfucci B; Bizeau A; Vergez S; Dupret-Bories A; Garrel R; Fakhry N; Santini L; Lallemant B; Chambon G; Sudaka A; Peyrade F; Saada-Bouzid E; Benezery K; Jourdan-Soulier F; Chapel F; Sophie Ramay A; Roger P; Galissier T; Coste V; Ben Lakdar A; Guerlain J; Temam S; Mirghani H; Gorphe P; Chamorey E; Culié D
Oral Oncol; 2021 Jan; 112():105041. PubMed ID: 33129057
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and survival unique to surgically treated p16+ oropharyngeal cancer.
Haughey BH; Sinha P
Laryngoscope; 2012 Sep; 122 Suppl 2():S13-33. PubMed ID: 22926949
[TBL] [Abstract][Full Text] [Related]
8. Impact of HPV-associated p16-expression and other clinical factors on therapeutic decision-making in patients with oropharyngeal cancer: A GETTEC multicentric study.
Culié D; Garrel R; Viotti J; Schiappa R; Chamorey E; Fakhry N; Lallemant B; Vergez S; Dupret-Bories A; Dassonville O; Poissonnet G; Santini J; Peyrade F; Benezery K; Sudaka A; Jourdan-Soulier F; Chapel F; Guelfucci B; Bozec A
Eur J Surg Oncol; 2018 Dec; 44(12):1908-1913. PubMed ID: 29871820
[TBL] [Abstract][Full Text] [Related]
9. Impact of chemotherapy regimen on treatment outcomes in patients with HPV-associated oropharyngeal cancer with T4 disease treated with definitive concurrent chemoradiation.
Bhattasali O; Ryoo JJ; Thompson LDR; Abdalla IA; Chen J; Iganej S
Oral Oncol; 2019 Aug; 95():74-78. PubMed ID: 31345397
[TBL] [Abstract][Full Text] [Related]
10. Confirmation of the eighth edition of the AJCC/UICC TNM staging system for HPV-mediated oropharyngeal cancer in Japan.
Mizumachi T; Homma A; Sakashita T; Kano S; Hatakeyama H; Fukuda S
Int J Clin Oncol; 2017 Aug; 22(4):682-689. PubMed ID: 28271391
[TBL] [Abstract][Full Text] [Related]
11. Determining optimal follow-up in the management of human papillomavirus-positive oropharyngeal cancer.
Frakes JM; Naghavi AO; Demetriou SK; Strom TJ; Russell JS; Kish JA; McCaffrey JC; Otto KJ; Padhya TA; Harrison LB; Trotti AM; Caudell JJ
Cancer; 2016 Feb; 122(4):634-41. PubMed ID: 26565997
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of the biomarker p16 in oropharyngeal squamous cell carcinoma.
Oguejiofor KK; Hall JS; Mani N; Douglas C; Slevin NJ; Homer J; Hall G; West CM
Clin Oncol (R Coll Radiol); 2013 Nov; 25(11):630-8. PubMed ID: 23916365
[TBL] [Abstract][Full Text] [Related]
13. Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer.
Buglione M; Maddalo M; Corvò R; Pirtoli L; Paiar F; Lastrucci L; Stefanacci M; Belgioia L; Crociani M; Vecchio S; Bonomo P; Bertocci S; Borghetti P; Pasinetti N; Triggiani L; Costa L; Tonoli S; Grisanti S; Magrini SM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):462-472. PubMed ID: 27986347
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the impact of smoking on disease-specific survival outcomes in patients with human papillomavirus-associated oropharyngeal cancer treated with transoral robotic surgery.
Roden DF; Hobelmann K; Vimawala S; Richa T; Fundakowski CE; Goldman R; Luginbuhl A; Curry JM; Cognetti DM
Cancer; 2020 Jan; 126(9):1873-1887. PubMed ID: 32032441
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of extranodal extension in human papillomavirus-associated oropharyngeal squamous cell carcinoma.
An Y; Park HS; Kelly JR; Stahl JM; Yarbrough WG; Burtness BA; Contessa JN; Decker RH; Koshy M; Husain ZA
Cancer; 2017 Jul; 123(14):2762-2772. PubMed ID: 28323338
[TBL] [Abstract][Full Text] [Related]
16. Human papilloma virus and survival of oropharyngeal cancer patients treated with surgery and adjuvant radiotherapy.
Broglie MA; Soltermann A; Haile SR; Huber GF; Stoeckli SJ
Eur Arch Otorhinolaryngol; 2015 Jul; 272(7):1755-62. PubMed ID: 24880469
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes and prognostic factors in cisplatin versus cetuximab chemoradiation for locally advanced p16 positive oropharyngeal carcinoma.
Barney CL; Walston S; Zamora P; Healy EH; Nolan N; Diavolitsis VM; Neki A; Rupert R; Savvides P; Agrawal A; Old M; Ozer E; Carrau R; Kang S; Rocco J; Teknos T; Grecula JC; Wobb J; Mitchell D; Blakaj D; Bhatt AD
Oral Oncol; 2018 Apr; 79():9-14. PubMed ID: 29598954
[TBL] [Abstract][Full Text] [Related]
18. Validation of the 8
van Gysen K; Stevens M; Guo L; Jayamanne D; Veivers D; Wignall A; Pang L; Guminski A; Lee A; Hruby G; Macleod P; Taylor A; Eade T
BMC Cancer; 2019 Jul; 19(1):674. PubMed ID: 31288767
[TBL] [Abstract][Full Text] [Related]
19. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
[TBL] [Abstract][Full Text] [Related]
20. Enhancing regional control in p16-negative oropharyngeal cancer: A propensity score-matched analysis of upfront neck dissection and definitive chemoradiotherapy.
Lee TL; Fang WC; Lee IC; Lirng JF; Chang CF; Hsu YB; Chu PY; Wang YF; Yang MH; Chang PM; Wang LW; Tai SK
J Chin Med Assoc; 2024 May; 87(5):516-524. PubMed ID: 38501795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
